Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Post by Canadian_101on Jul 27, 2020 9:42am

237 Views

Post# 31323190

7 Analysts says ACSTI is a BUY

Acasti Pharma Inc (NASDAQ:ACST) Receives Consensus Rating of “Buy” from Brokerages

Posted by Max Byerly on Jul 27th, 2020

Acasti Pharma logo Acasti Pharma Inc (NASDAQ:ACST) has been given an average rating of “Buy” by the seven analysts that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $2.68